Graphic: Viktoria Nikolova for Endpoints News
February 14, 2024 11:24 AM ESTUpdated 04:55 PM
China
In Focus
Diagnostics

In clash over sci­ence and na­tion­al se­cu­ri­ty, Chi­nese ri­val to Il­lu­mi­na strug­gles with US ex­pan­sion

Jared Whitlock

Features Editor

The pitch from Chi­na’s MGI Tech to US labs seems ap­peal­ing: Its DNA se­quenc­ing ma­chines can de­code a genome for around $100, an im­por­tant bench­mark …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times